Clinical Trials Directory
Recruiting
Conditions
Sponsors
Search
About
Trials
/
Sponsors
/ HighTide Biopharma Pty Ltd
HighTide Biopharma Pty Ltd
Industry · 12 registered clinical trials.
Status
Trial
Phase
Started
Completed
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequa
T2DM (Type 2 Diabetes Mellitus)
Phase 3
2024-06-04
Completed
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Cont
Type 2 Diabetes Mellitus
Phase 3
2023-11-13
Completed
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
T2DM (Type 2 Diabetes Mellitus)
Phase 3
2023-11-05
Completed
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabete
Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
Phase 2
2022-12-27
Completed
A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controll
Type 2 Diabetes Mellitus
Phase 2
2022-03-31
Completed
Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
Primary Biliary Cholangitis, Primary Biliary Cirrhosis, Cholangitis
Phase 2
2021-05-27
Withdrawn
A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis, Cholangitis, Cholangitis, Sclerosing
Phase 2
2021-03-01
Completed
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease
Phase 2
2018-11-26
Completed
A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia
Hypercholesterolemia
Phase 1 / Phase 2
2018-04-13
Completed
A POC and Dose-Ranging Study of HTD1801 in PSC Patients
Primary Sclerosing Cholangitis (PSC)
Phase 2
2018-02-09
Completed
A Study of HTD1801 in Healthy Subjects
Primary Sclerosing Cholangitis
Phase 1
2017-03-24
Completed
Study of HTD4010 in Healthy Volunteers
Type 2 Diabetes Mellitus
Phase 1
2015-10-01